Back to results
US 2026/0027156 A1Published application
Bispecific chimeric antigen receptors targeting bcma and cd19
AssigneeAbelzeta Inc.
InventorsYihong YAO, Jiaqi HUANG, Shigui ZHU, Xin YAO, Xiaobing LUO, Yanfeng LI
Life of this patent
Estimating the term…
Abstract
The present disclosure provides bispecific chimeric antigen receptors targeting BCMA and CD19. The CAR may comprise an scFv targeting BCMA and an scFv targeting CD19, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.
Claims22
A bispecific chimeric antigen receptor (CAR), comprising:
- (i) an anti-BCMA antigen-binding region which comprises a light chain variable region (VL1) and a heavy chain variable region (VH1), wherein VL1 comprises three complementarity determining regions (CDRs), CDR1, CDR2 and CDR3, having amino acid sequences about 80% to about 100% identical to the amino acid sequences set forth in SEQ ID NO:
- 2, SEQ ID NO:
- 4, SEQ ID NO:
- 6, respectively, and wherein VH1 comprises three CDRs, CDR1, CDR2 and CDR3, having amino acid sequences about 80% to about 100% identical to the amino acid sequences set forth in SEQ ID NO:
- 9, SEQ ID NO:
- 11, SEQ ID NO:
- 13, respectively;
- and
- (ii) an anti-CD19 antigen-binding region which comprises a light chain variable region (VL2) and a heavy chain variable region (VH2), wherein VL2 comprises three complementarity determining regions (CDRs), CDR1, CDR2 and CDR3, having amino acid sequences about 80% to about 100% identical to the amino acid sequences set forth in SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, respectively, and wherein VH2 comprises three CDRs, CDR1, CDR2 and CDR3, having amino acid sequences about 80% to about 100% identical to the amino acid sequences set forth in SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, respectively.
12 more elements
Dependencies are inferred from the claim text.